Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

NetScientific PLC 's Wanda sets up scientific advisory board

Wanda has developed a way to monitor digitally people with congestive heart failure and other chronic conditions
NetScientific PLC 's Wanda sets up scientific advisory board
Wanda has attracted a heavyweight panel to advise it

Wanda, one of healthcare tech investor NetScientific plc’s (LON:NSCI) core investments, has formed a scientific advisory board to guide the management  team.

The board will include distinguished physicians, health economics scientists, and technologists committed to advancing clinical outcomes for individuals with chronic disease.

Wanda has developed a way to digitally monitor people with congestive heart failure and other chronic conditions.

Last month, it announced the launch of a software platform to improve cancer care in collaboration with leading US hospital group Dignity Health.

Francois Martelet, NetScientific's chief executive, said: "Wanda's technology has broad potential to simplify and improve the lives of people confronted with chronic conditions and, in the near term, to help patients with congestive heart failure and their physicians to monitor risk and predict and prevent readmission to hospital.  

“The calibre of the new SAB members is testament to the quality of the Wanda platform and we look forward to their input as Wanda develops into a world-leading digital health business."

Members of the new Wanda board include: Constanzo DiPerna, - medical director of Dignity Health Cancer Institute of Greater Sacramento; Clyde Wesp, executive clinical strategist at Jacobus Consulting; Janki Shah, founder and director of the UCLA Northwest Valley Women's Heart Health Program and Jeff Moreland, CEO and chief patient officer for Patient Engagement Advisors (PEA).

View full NSCI profile View Profile

Netscientific PLC Timeline

Related Articles

blood
April 01 2018
The company is in the process of raising £5mln, with a possible further £1mln through a share issue at 52.5p
affimer technology
May 01 2018
The company is making progress with its lead immuno-oncology programmes
test tubes
January 22 2018
Under former chief executive Peter George and his successor Shaun Chilton, it has been transformed via a series of well-judged, quickly integrated and, crucially, cash generative acquisitions

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use